clinical trials involving devices and combination products across the US, UK, and EU. Targeted at clinical operations, regulatory affairs, and medical affairs professionals, this article clarifies how to navigate complex regulatory frameworks such as those from the FDA, EMA, and MHRA while leveraging innovative trial designs like platform trial design. It also contextualizes the application of navigator trials in notable examples such as the katherine clinical trial and pfizer vaccine trials, ensuring adherence to Good Clinical Practice (GCP) and regulatory expectations. Understanding these elements is critical for ensuring scientific rigor, patient safety, and regulatory compliance in global clinical trial programs involving combination products and devices.

1. Context and Core Definitions for Device & Combination Product Regulations and Navigator Trial

To effectively integrate a navigator trial into a global clinical trial strategy, it is essential first to understand foundational concepts. A navigator trial is a trial design framework that facilitates adaptive, flexible, and efficient evaluation of multiple interventions or device-combination product configurations within a single overarching protocol. This approach often incorporates elements of platform trial design, allowing for dynamic addition or removal of treatment arms based on interim data.

Device and Combination Products are regulated entities that combine drugs, biologics, and/or devices. The US FDA defines combination products as therapeutic and diagnostic products that combine drugs, devices, and/or biological products. In the EU, the Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR) govern devices, while combination products are assessed under both medicinal product and device frameworks. The UK’s MHRA aligns closely with EU regulations post-Brexit but maintains specific guidance for combination products.

Understanding these definitions is crucial because navigator trials often involve investigational devices or combination products, which must comply with applicable regulatory pathways. For example, a sting agonist clinical trial testing a novel immunomodulatory device combined with a drug component requires adherence to both device and medicinal product regulations.

In practice, integrating a navigator trial design within device and combination product regulations ensures that trial protocols, informed consent, and data collection reflect the complexity of the interventions while maintaining compliance with regulatory standards such as FDA’s 21 CFR Parts 50 and 812, EMA’s Clinical Trial Regulation (EU-CTR), and UK MHRA’s Clinical Trial Authorisation (CTA) requirements.

2. Regulatory and GCP Expectations in US, EU, and UK

Regulatory agencies expect rigorous adherence to Good Clinical Practice (GCP) and specific device/combination product regulations when conducting navigator trials. In the US, the FDA’s Center for Devices and Radiological Health (CDRH) and Center for Drug Evaluation and Research (CDER) provide guidance on combination product development. Key regulations include 21 CFR Part 812 for Investigational Device Exemptions (IDE) and 21 CFR Parts 50 and 56 for human subject protections.

The EU Clinical Trial Regulation (EU-CTR) No 536/2014 harmonizes clinical trial requirements across member states, emphasizing transparency, safety monitoring, and data integrity. The MDR (Regulation (EU) 2017/745) governs device aspects and mandates conformity assessment and post-market surveillance, which intersect with clinical trial activities.

In the UK, the MHRA oversees clinical trials involving devices and combination products under the UK Clinical Trial Regulations and Medical Devices Regulations 2002 (as amended). MHRA guidance emphasizes risk-based approaches, safety reporting, and compliance with GCP principles.

Across these regions, navigator trials must incorporate comprehensive risk assessments, robust monitoring plans, and clear delineation of responsibilities among sponsors, CROs, and investigators. Adherence to ICH E6(R3) and E8(R1) guidelines on trial design and quality management is also expected, ensuring that adaptive designs like navigator trials maintain scientific validity and participant safety.

3. Practical Design and Operational Considerations for Navigator Trials with Device & Combination Products

Implementing a navigator trial within the context of device and combination product regulations requires meticulous planning and coordination. The following checklist outlines critical steps for clinical operations and regulatory teams:

1. Define the Trial Objectives and Scope: Clearly articulate the clinical questions, including device and drug components, and how the navigator trial design will enable adaptive evaluation.
2. Engage Regulatory Authorities Early: Seek scientific advice or pre-submission meetings with FDA, EMA, and/or MHRA to align on trial design, endpoints, and regulatory pathways.
3. Develop a Comprehensive Protocol: Include detailed descriptions of device specifications, combination product components, platform trial design elements, adaptive algorithms, and safety monitoring plans.
4. Establish Risk Management Plans: Identify potential risks related to device use, combination product interactions, and adaptive design changes. Define mitigation strategies and escalation pathways.
5. Ensure Robust Informed Consent: Address the complexity of the navigator trial and device/combination product risks in patient-facing materials, ensuring comprehension and voluntariness.
6. Coordinate Multidisciplinary Teams: Assign clear roles and responsibilities for clinical operations, regulatory affairs, data management, and medical affairs to manage the trial’s complexity.
7. Implement Quality Management Systems: Develop SOPs for device handling, combination product administration, adaptive trial conduct, and data integrity assurance.
8. Plan for Data Monitoring and Interim Analyses: Define Data Monitoring Committee (DMC) charters and interim analysis schedules to support adaptive decision-making.
9. Train Investigators and Site Staff: Provide targeted training on device use, combination product administration, and navigator trial procedures.
10. Prepare for Regulatory Submissions: Compile comprehensive documentation including IDE applications (US), Clinical Trial Applications (EU/UK), and risk assessments.

For example, in a sting agonist clinical trial involving a novel immunomodulatory device combined with a drug, operational workflows must ensure device calibration, drug storage compliance, and synchronized dosing schedules. The platform trial design elements enable seamless addition or removal of treatment arms based on interim efficacy or safety data.

4. Common Pitfalls, Inspection Findings, and How to Avoid Them

Regulatory inspections frequently identify challenges in navigator trials involving device and combination products. Common pitfalls include:

• Incomplete or Ambiguous Protocols: Lack of clarity on device specifications, combination product interactions, or adaptive design rules can lead to protocol deviations and regulatory non-compliance.
• Inadequate Risk Assessments: Failure to identify and mitigate device-related risks or combination product safety concerns compromises subject safety and data reliability.
• Insufficient Training: Site staff unfamiliarity with device operation or adaptive trial procedures increases the risk of errors and protocol violations.
• Poor Documentation of Adaptive Changes: Inadequate recording of interim decisions and protocol amendments undermines data integrity and audit readiness.
• Non-compliance with Regulatory Submissions: Delays or omissions in IDE amendments or Clinical Trial Applications reflecting trial modifications can result in enforcement actions.

To avoid these issues, teams should implement rigorous SOPs addressing device handling, adaptive trial governance, and regulatory communication. Regular training refreshers and internal audits help maintain compliance. Leveraging electronic trial master files (eTMF) and centralized data monitoring supports transparency and traceability of navigator trial adaptations.

5. US vs EU vs UK Nuances and Real-World Case Examples

While the US, EU, and UK share common regulatory principles, notable differences impact navigator trial execution:

• Regulatory Submission Processes: The FDA requires Investigational Device Exemption (IDE) submissions for device studies, often with separate drug INDs for combination products. The EU uses the Clinical Trial Information System (CTIS) under EU-CTR, integrating device and medicinal product assessments. The UK MHRA mandates Clinical Trial Authorisation (CTA) with device-specific annexes.
• Adaptive Design Acceptance: The FDA has published guidance supporting adaptive designs but emphasizes pre-specification and control of type I error. EMA and MHRA also support adaptive designs but require detailed statistical analysis plans and risk mitigation.
• Post-Market Surveillance Integration: EU MDR and UK regulations require post-trial device vigilance and periodic safety updates, which may be less prescriptive in the US context.

Case Example 1: A multinational katherine clinical trial incorporated a navigator trial design to evaluate multiple device-drug combinations for oncology indications. Early engagement with FDA and EMA enabled harmonized protocol development and streamlined regulatory submissions, reducing approval timelines.

Case Example 2: In a pfizer vaccine trials platform trial design, adaptive elements allowed rapid assessment of device delivery systems combined with vaccine formulations. MHRA oversight ensured compliance with UK-specific device regulations, while centralized data monitoring facilitated real-time safety assessments.

6. Implementation Roadmap and Best-Practice Checklist

To operationalize navigator trials within device and combination product regulations, follow this stepwise roadmap:

1. Initiate Cross-Functional Planning: Assemble teams from clinical operations, regulatory affairs, medical affairs, biostatistics, and quality assurance.
2. Conduct Regulatory Landscape Analysis: Map applicable regulations and guidance documents for all target regions (US, EU, UK).
3. Develop Integrated Protocol and Risk Management Plan: Incorporate device and combination product specifics, adaptive design elements, and safety monitoring.
4. Engage with Regulatory Agencies: Schedule pre-submission meetings to align on trial design and regulatory expectations.
5. Prepare Comprehensive Submission Dossiers: Include IDE applications, Clinical Trial Applications, and risk assessments.
6. Implement Training Programs: Educate site staff and investigators on device use, combination product handling, and navigator trial procedures.
7. Establish Quality Control and Monitoring: Deploy centralized monitoring, interim analysis oversight, and audit readiness processes.
8. Maintain Transparent Documentation: Record all adaptive changes, regulatory communications, and safety reports systematically.
9. Conduct Periodic Reviews and Updates: Update protocols and SOPs as necessary based on interim data and regulatory feedback.

Below is a practical checklist summarizing key elements for navigator trial integration:

• Define device and combination product regulatory pathways early.
• Incorporate adaptive design principles compliant with FDA, EMA, and MHRA guidance.
• Develop detailed protocols addressing device specifications and combination product interactions.
• Implement comprehensive risk management and safety monitoring plans.
• Engage regulatory authorities proactively for alignment and feedback.
• Train clinical and site teams on device handling and adaptive trial procedures.
• Ensure robust documentation of all trial adaptations and regulatory submissions.
• Utilize centralized data monitoring and quality assurance systems.
• Prepare for post-market surveillance and vigilance reporting as applicable.

7. Comparison Table: Regulatory Considerations for Navigator Trials Involving Device & Combination Products in US, EU, and UK

Aspect	US (FDA)	EU (EMA/EU-CTR)	UK (MHRA)
Regulatory Submission	IDE for devices; IND for drugs; combination product coordination	Clinical Trial Application via CTIS; device conformity under MDR	Clinical Trial Authorisation with device annex; alignment with MDR
Adaptive Design Guidance	FDA guidance on adaptive designs; emphasis on statistical rigor	EMA supports adaptive designs; requires detailed SAP and risk plans	MHRA endorses adaptive designs; requires clear pre-specification
Device Risk Management	FDA 21 CFR Part 812; device-specific safety monitoring	MDR mandates risk management and post-market surveillance	UK MDR enforces risk management and vigilance reporting
Trial Oversight	IRB review; Data Monitoring Committees; FDA inspections	Ethics Committee and Competent Authority review; EMA inspections	Research Ethics Committee and MHRA review; inspections

Key Takeaways for Clinical Trial Teams

• Early and thorough integration of navigator trial design with device and combination product regulations is essential for global compliance.
• Aligning with FDA, EMA, and MHRA guidance reduces regulatory risk and supports efficient trial conduct.
• Comprehensive training and SOPs addressing device handling and adaptive trial procedures mitigate common operational pitfalls.
• Understanding regional nuances enables harmonized multinational trial strategies and facilitates regulatory acceptance.